Eden M D Biltibo,Malini Surapaneni,Samer Al Hadidi et al.
Eden M D Biltibo et al.
Treatment of multiple myeloma (MM) has evolved significantly over the past few decades. Up-front treatment options expanded from doublet regimens to triplets and now to quadruplets. Monoclonal antibodies have significantly contributed to th...
Connecting the Dots: Practical Strategies for Academic and Community Oncology Synergy to Advance Multidisciplinary Management in Immunotherapy Toxicity Care [0.03%]
携手并进：推动免疫治疗毒性综合管理的现实策略
Danielle Brazel,Vera Kazakova,Magdalena Fay et al.
Danielle Brazel et al.
Immunotherapy has significantly affected cancer treatment and survival rates, accompanied by an increase in immune-related adverse events (irAEs) requiring new management strategies. irAEs can affect various organ systems and have varying s...
Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trials [0.03%]
人工智能与机器学习在肿瘤临床试验设计和提高受试者代表性方面的创新改善
Tali Azenkot,Donna R Rivera,Mark D Stewart et al.
Tali Azenkot et al.
The integration of artificial intelligence (AI) and machine learning (ML) in oncology clinical trials is rapidly evolving alongside the broader field. For example, AI-driven adaptive trial designs may allow for real-time modifications based...
Bispecific Antibodies in Non-Small Cell Lung Cancer: From Targeted Innovation to Real-World Integration [0.03%]
双特异抗体在非小细胞肺癌中的应用：从靶向创新到实际整合
Jennifer W Carlisle,Zachary Wolner,Sagal Pannu et al.
Jennifer W Carlisle et al.
Bispecific antibodies have ushered in a transformative era in treating non-small cell lung cancer (NSCLC), enabling dual-pathway targeting with promising clinical outcomes in previously refractory disease subsets. Recent US Food and Drug Ad...
Artificial Intelligence in the Clinic: Creating Harmony or Just Adding Noise? [0.03%]
临床中的人工智能：创造和谐还是仅仅增加噪音？
Mariam Afzal,Katy E French,Larry E Bilbrey et al.
Mariam Afzal et al.
Although still limited, the integration of artificial intelligence (AI) in health care has rapidly expanded in the past few years, especially in oncology clinics. In this article, AI refers to the development and implementation of computer ...
Oncology and Suffering: Strategies on Coping With Grief for Health Care Professionals [0.03%]
肿瘤学与苦难：医护人员应对悲伤的策略
Keri O Brenner,Abigail Nathanson,Mikołaj Sławkowski-Rode
Keri O Brenner
This article comprises three integrated sections exploring the multidimensional suffering experienced in oncology-from the perspective of both patients and health care professionals. It explores how oncology clinicians can better understand...
Addressing Barriers in Palliative Care for Rural and Underserved Communities [0.03%]
农村和医疗资源匮乏地区缓和医疗障碍应对措施
Matthias Weiss,Susan Sabo-Wagner,Julia Frydman et al.
Matthias Weiss et al.
Thirty-two million Americans live in rural counties and have no access to multidisciplinary cancer care, and patients with cancer describe a greater number of unfavorable social determinants of health (SDoH), experience more serious financi...
Advancing Perioperative Treatment Options for Localized Muscle-Invasive Bladder Cancer: A Step Forward [0.03%]
肌 invasive 膀胱癌手术前后的治疗选项的发展：迈出一步
Maria J Ribal,Jonathan Rosenberg,Tarek Ajami et al.
Maria J Ribal et al.
Muscle-invasive bladder cancer (MIBC) is an aggressive disease, with substantial recurrence risk after radical cystectomy and pelvic lymph node dissection alone. In cisplatin-eligible patients, administration of neoadjuvant cisplatin-based ...
Heikki Joensuu,Hirotaka Miyashita,Suzanne George et al.
Heikki Joensuu et al.
GI stromal tumors (GISTs) are mesenchymal neoplasms with variable natural histories, originating in the GI tract, most commonly in the stomach. They are frequently characterized by KIT or platelet-derived growth factor receptor alpha (PDGFR...
Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care [0.03%]
临床试验可及性实践指南：让受试者参与成为护理标准
Hedyeh Ebrahimi,Jodie Allen,Yelak Biru et al.
Hedyeh Ebrahimi et al.
Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this multidisciplinary perspective piece, stakeholders from p...